Published Studies Related to Quixin (Levofloxacin Ophthalmic)
Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a
randomized, double-blind, placebo-controlled trial. 
study of the effect of levofloxacin in patients with stable COPD... CONCLUSION: In stable COPD, levofloxacin treatment causes a short-term reduction
Efficacy of levofloxacin in the treatment of BK viremia: a multicenter,
double-blinded, randomized, placebo-controlled trial. 
determine the efficacy of levofloxacin in the treatment of BK viremia... CONCLUSIONS: A 30-day course of levofloxacin does not significantly improve BK
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and
safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the
treatment of patients with community-acquired bacterial pneumonia. 
Solithromycin, a new macrolide, and the first fluoroketolide in clinical
development, with activity against macrolide-resistant bacteria, was tested in
132 patients with moderate to moderately severe community-acquired bacterial
pneumonia (CABP) in a multicenter, double-blind, randomized phase 2 study...
Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary
tract infections: a multicentre, double-blind, randomized controlled clinical
respiratory and urinary infections of Chinese patients... CONCLUSION: Prulifloxacin is as effective and well tolerated as levofloxacin in
Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. [2011.08]
OBJECTIVES: First-line standard eradication efficacy with lansoprazole, amoxicillin and clarithromycin regressed over 10 years. The aim of this study was to evaluate the efficacy and tolerability of a levofloxacin-based regimen in patients with peptic ulcer after failure of the standard first-line H.pylori eradication therapy in a country with a high rate of infection... CONCLUSION: OLA regimen eradication rate was successful only in 40% of patients who failed in the first-line eradication. New eradication treatment strategies must be performed, at least in Turkey.
Clinical Trials Related to Quixin (Levofloxacin Ophthalmic)
"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". [Recruiting]
A multicenter, prospective, non-inferiority, randomized and open clinical trial comparing
levofloxacin with isoniazid in the treatment of latent tuberculosis infection in patients
eligible for liver transplantation.
Patients over 18 years of age on the waiting list for liver transplantation.
Sample size: n=870 patients.
Levofloxacin treatment of latent tuberculosis infection, begun while on the waiting list for
liver transplantation, is safer and not less effective than isoniazid treatment begun after
transplantation when liver function is stable.
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis [Active, not recruiting]
The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg
for 2 weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the
treatment of chronic prostatitis.
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients [Recruiting]
Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB
(MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However,
there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among
MDR-TB patients. The investigators will compare the efficacy of levofloxacin and
moxifloxacin through a prospective multicenter randomized open label phase III trial.
A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects [Completed]
The primary objective of the study was to assess the bioequivalence of the oral suspension
formulation, the oral solution formulation, and the marketed tablet formulation of
levofloxacin, with the marketed tablet as the reference.
Ceftidoren Versus Levofloxacin in the Treatment of Patients With Acute Exacerbations of Chronic Bronchitis (AECB) [Not yet recruiting]
40 outpatients with exacerbations of Chronic Obstructive Pulmonary Diseases (COPD) will be
enrolled in a multi-centre, open-label, randomised, pilot study. Two treatments will be
compared, ceftidoren 200 mg bid for 5 days and levofloxacin 500 mg once daily for 7 days.
Primary objective of the study is to evaluate the effects of the treatment on serum
inflammatory biomarkers and the secondary objective is to evaluate the clinical and
microbiological efficacy at the Test Of Cure visit (TOC), DAY 7-10 (end of treatment).
The study foresees 4 visits: Visit 1 (enrolment, day 1 of treatment); Visit 2 (day 2-4);
Visit 3 (Test Of Cure-TOC visit, day 7-10 end of treatment), Visit 3 (Late Post Therapy
assessment, Day 28-30).
The primary parameter to test the efficacy of the study medications will be the assessment
of the speed of reduction of inflammatory parameters (CRP, PCT and KL6). Every reduction of
10% will be taken into account. The comparison between treatments will be performed at visit
2 and 3.